Monograph
J07AM51 - Tetanus Toxoid, Combinations with Diphtheria Toxoid |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the tetanus toxoid, combinations with diphtheria toxoid vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Purified tetanus toxoid and diphtheria toxoid.
Therapeutic characteristics
The tetanus- and diphtheria –toxoid combination vaccine is indicated for booster vaccination against diphtheria and tetanus of individuals from the age of five years onwards. It is administered as a single intramuscular injection.
Metabolism and pharmacokinetics
The tetanus toxoid, combinations vaccine is not metabolized by the cytochrome P450 system.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | Norwegian medicines agency. Summary of Product Characteristics (SPC). diTeBooster.
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
United Kingdom
Denmark
Norway
Poland
Finland
Latvia
Serbia© NAPOS 2024